Publications by authors named "Don Berry"

Claim this Profile
T
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.
Angela DeMichele, Amy S Clark, Emily Shea, Lauren J Bayne, Christopher J Sterner, Lindsay R Berry, Don Berry

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch, Don Berry

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Aaron C Tan, Stephen J Bagley, Patrick Y Wen, Michael Lim, Michael Platten, Don Berry

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
Wen Li, David C Newitt, Jessica Gibbs, Lisa J Wilmes, Ella F Jones, Don Berry

NPJ Breast Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Don Berry

NPJ Breast Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Denise M Wolf, Christina Yau, Ashish Sanil, Annuska Glas, Emanuel Petricoin, Don Berry

NPJ Breast Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
Angela DeMichele, Douglas Yee, Melissa Paoloni, Don Berry, Laura J Esserman

Clin Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.
Zachary Skrivanek, Scott Berry, Don Berry, Jenny Chien, Mary Jane Geiger

J Diabetes Sci Technol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panel discussion 2.
Susan Ellenberg, Bryan Luce, Tom Fleming, Jay Siegel, Brian Strom, Don Berry

Clin Trials· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Gretchen Kimmick, Mark J Ratain, Don Berry, Susan Woolf, Larry Norton

Invest New Drugs· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis